Volume | 378,146 |
|
|||||
News | - | ||||||
Day High | 8.77 | Low High |
|||||
Day Low | 8.45 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Voyager Therapeutics Inc | VYGR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
8.65 | 8.45 | 8.77 | 8.51 | 8.80 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
5,461 | 378,146 | US$ 8.54 | US$ 3,229,304 | - | 6.06 - 14.07 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:16:30 | 3 | US$ 8.60 | USD |
Voyager Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
462.1M | 54.30M | - | 250.01M | 132.33M | 2.44 | 3.49 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Voyager Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYGR Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.39 | 9.06 | 8.20 | 8.68 | 312,100 | 0.12 | 1.43% |
1 Month | 8.67 | 9.06 | 7.68 | 8.41 | 375,082 | -0.16 | -1.85% |
3 Months | 9.46 | 10.66 | 7.26 | 8.65 | 495,532 | -0.95 | -10.04% |
6 Months | 7.96 | 11.72 | 7.01 | 8.80 | 708,201 | 0.55 | 6.91% |
1 Year | 13.30 | 14.07 | 6.06 | 9.05 | 518,713 | -4.79 | -36.02% |
3 Years | 4.73 | 14.3398 | 2.46 | 5.84 | 879,334 | 3.78 | 79.92% |
5 Years | 24.62 | 28.79 | 2.46 | 7.12 | 683,497 | -16.11 | -65.43% |
Voyager Therapeutics Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. |